---
document_datetime: 2023-09-21 18:42:15
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/trazec-epar-procedural-steps-taken-authorisation_en.pdf
document_name: trazec-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3633177
conversion_datetime: 2025-12-28 13:54:36.307205
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The applicant Novartis Europharm Ltd submitted on 17 October 2000 an application for Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Trazec, through the centralised procedure. After agreement by the CPMP on 25 March 1999 for nateglinide, this  medicinal  product  has  been  referred  to  Part  B  of  the  Annex  to  Council  Regulation  No  (EEC) 2309/93 of 22 July 1993 as amended.

<!-- image -->

Medicinal product no longer authorised The Rapporteur and Co-Rapporteur appointed by the CPMP were: Rapporteur: Dr. Mary Teeling                      Co-Rapporteur:        Prof. Cristina Sampaio Scientific Advice: The applicant  received  Scientific  Advice  from  the  CPMP  on  18  April  1996.  The  Scientific  Advice pertained to parts II and IV of the dossier. Licensing status: Trazec has been given a Marketing Authorisation in Japan in June 1999 under the name Fastic, Starsis. 2. Steps taken for the assessment of the product · The procedure started on 17 October 2000. · During  the  CPMP  meeting  on  12  December  2000,  outstanding  issues  were  addressed  by  the applicant during a hearing before the CPMP. · During  the  meeting  on  12-14  December  2000 the  CPMP,  in  the  light  of  the  overall  data submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  by majority vote for granting a Marketing Authorisation to Trazec on 14 December 2000.